| Document Date: 2014-03-03 16:19:48
Open Document File Size: 432,79 KBShare Result on Facebook
City RESULTS LEXINGTON / / Company Synageva BioPharma Corp. / / Country United States / / Currency USD / / Event Conference Call / FDA Phase / Earnings Announcement / Earnings Guidance / / IndustryTerm manufacturing facility / biopharmaceutical company developing therapeutic products / drug product / developed technology / manufacturing platform / manufacturing capabilities / / MedicalCondition mucopolysaccharidosis IIIB / accelerated atherosclerosis / LAL Deficiency LAL Deficiency / rare diseases / storage disease / disease / cirrhosis / lysosomal acid lipase deficiency / Cholesteryl Ester Storage Disease / MPS IIIB The mucopolysaccharidoses / Wolman disease / rare disorders / diseases / deficiency / LAL Deficiency / B syndrome / / MedicalTreatment enzyme replacement therapy / biologic therapies / / Organization European Medicines Agency / U.S. Food and Drug Administration / FDA / Ministry of Health / / Person MPS IIIB / / / Position general business update / animal model / / Product Fuzeon / SBC-103 / / ProvinceOrState Massachusetts / / Technology alpha / / URL www.synageva.com / /
SocialTag |
SYNAGEVA BIOPHARMA™ REPORTS 2013 FULL YEAR FINANCIAL RESULTS LEXINGTON, Mass., March 3, [removed]Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for